Drug Profile
AVI 4065
Alternative Names: AVI-4065Latest Information Update: 13 Aug 2007
Price :
$50
*
At a glance
- Originator AVI BioPharma
- Class Antisense oligonucleotides; Antivirals
- Mechanism of Action Virus replication inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Hepatitis C
Most Recent Events
- 13 Aug 2007 Discontinued - Phase-I/II for Hepatitis C treatment in USA (SC)
- 20 Nov 2006 Clinical data have been added to the pharmacokinetics section
- 05 Oct 2006 Interim results from a phase I/II clinical trial in patients with Hepatitis C Virus Infection have been added to the adverse events, pharmacokinetics and Viral Infections therapeutic trials sections